Medical/Pharmaceuticals
Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line
BASKING RIDGE, N.J., Feb. 6, 2026 /PRNewswire/ -- Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL. PYQUVI, a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older, is bioequi...
2026-02-06 19:59
5199
PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101
SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO:Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial inthe United ...
2026-02-06 15:20
8565
Sky Labs Signs Exclusive Distribution Agreement with Otsuka Pharmaceutical for 'CART BP pro' in Japan
- Secures distribution agreement to launch CART BP pro in the Japanese hospital and clinic market - Leveraging proven technology with adoptions in 1,700+ medical institutions and national health insurance coverage in Korea SEOUL, South Korea, Feb. 5, 2026 /PRNewswire/ -- Sky Labs Inc. (CEO Jack ...
2026-02-06 09:00
6547
LifeZoom Introduces the Oclux Red Light Eye Mask--A Naturally Restorative, Aesthetics-Driven Solution for the Effects of Screen-Based Life
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- LifeZoom, a natural-restorative brand, today launches Oclux, a red light eye mask that expands the company's red light product lineup. Positioned as a holistic solution that balances visual aesthetics, user experience, and daily rhythms, Oclux is designed to...
2026-02-05 22:12
7536
Jin Medical CEO Fireside Chat
CHANGZHOU, China, Feb. 5, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment hosted a CEO Fireside Chat onFebruary 2, 2026 where the CEO sha...
2026-02-05 21:57
9177
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
* NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. * Unlike ISM8969, Insilico's brain-penetrant NLR...
2026-02-05 21:00
8594
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters:Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive developm...
2026-02-05 19:44
9016
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026
Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechno...
2026-02-05 17:09
10089
Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism
BEIJING, Feb. 5, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study inNature that pinpoints the core functional circuit underlying Parkinson's disease (PD). The findings redefine the biological...
2026-02-05 13:00
6190
Yuyu Pharma Invests in James & Ella, Advancing Its Global Expansion Into Premium Pet Wellness
SEOUL, South Korea, Feb. 4, 2026 /PRNewswire/ -- Yuyu Pharma announced today a strategic investment in James & Ella, theUnited Kingdom's fastest-growing freeze-dried pet nutrition company. Founded by entrepreneurJames Middleton, James & Ella has rapidly established itself as the leader of the UK ...
2026-02-04 22:00
7801
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profi...
2026-02-04 08:01
9701
United Imaging Healthcare North America Welcomes John Campbell as Vice President of Customer Success
HOUSTON, Feb. 3, 2026 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy solutions, is pleased to announce that John Campbell recently joined the organization as Vice President of Customer Success,North America. In this role, he will support United Imaging...
2026-02-04 01:00
8614
Akso Health Group Announces Launch of Exploratory Global Patient Support Initiative
QINGDAO, China, Feb. 3, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Adopting an integrated model of "Traditional ...
2026-02-03 22:00
8811
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment ofUSD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in d...
2026-02-03 22:00
8361
CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access
OSLO, Norway and INCHEON, South Korea, Feb. 3, 2026 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufact...
2026-02-03 21:00
8914
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors
Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In Global, For Global" collaboration strategy. NEWARK, Del. and NANJING, China, Feb. 3, 2026 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a globa...
2026-02-03 17:31
9052
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered inSan Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a key strategic partner, joined hands with multiple enterpr...
2026-02-02 23:00
9111
SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech
- SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, plus tiered royalties - Genentech wil...
2026-02-02 20:00
5597
Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery"
SHANGHAI, Jan. 31, 2026 /PRNewswire/ -- Amid the surging wave of innovation in China's biopharmaceutical industry, a decade is long enough to witness the full evolution of a sector—from its initial emergence and growth to fundamental transformation. In 2015, as regulatory reform ignited local in...
2026-01-31 16:15
12305
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, to...
2026-01-30 21:00
11331
Week's Top Stories
Most Reposted
DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 279 media titles]
2026-10-07 11:50Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 262 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24261